

2010

## Preclinical Evaluation of Novel All-in-one Formulations of 5-Fluorouracil and Folinic Acid with Reduced Toxicity Profiles - Supplementary Data

Tamantha K. Stutchbury  
*University of Wollongong, [tamantha@uow.edu.au](mailto:tamantha@uow.edu.au)*

Kara L. Vine  
*University of Wollongong, [kara@uow.edu.au](mailto:kara@uow.edu.au)*


Julie M. Locke  
*University of Wollongong, [jlocke@uow.edu.au](mailto:jlocke@uow.edu.au)*

Jeremy S. Chrisp  
*Jeremy Chrisp & Associates, Hunters Hill*

J. B. Bremner  
[jbremner@uow.edu.au](mailto:jbremner@uow.edu.au)

*See next page for additional authors*

Follow this and additional works at: <https://ro.uow.edu.au/scipapers>

 Part of the [Life Sciences Commons](#), [Physical Sciences and Mathematics Commons](#), and the [Social and Behavioral Sciences Commons](#)

---

### Recommended Citation

Stutchbury, Tamantha K.; Vine, Kara L.; Locke, Julie M.; Chrisp, Jeremy S.; Bremner, J. B.; Clingan, P; and Ranson, Marie: Preclinical Evaluation of Novel All-in-one Formulations of 5-Fluorouracil and Folinic Acid with Reduced Toxicity Profiles - Supplementary Data 2010.  
<https://ro.uow.edu.au/scipapers/177>

---

## Preclinical Evaluation of Novel All-in-one Formulations of 5-Fluorouracil and Folinic Acid with Reduced Toxicity Profiles - Supplementary Data

### Abstract

**Objectives:** 5-Fluorouracil (5-FU) in combination with its synergistic biomodulator folinic acid maintains a pivotal position in cancer chemotherapy. However, clinical limitations persist with the administration of these drugs in combination including phlebitis and catheter blockages, which are associated with reduced efficacy and/or quality of life for patients. We have previously reported novel all-in-one, pH neutral, parenteral 5-FU and folinic acid formulations (termed Fluorodex) incorporating beta-cyclodextrins. Fluorodex maintains potency while overcoming the accepted incompatibility of 5-FU and folinic acid.

**Methods:** We performed toxicological, pharmacokinetic and biodistribution, and efficacy evaluations of Fluorodex compared to 5-FU:folinic acid using several administration routes and schedules in two rodent models. These were compared to dose-matched sequential administration of 5-FU:folinic acid.

**Results:** Fluorodex showed bioequivalence to 5-FU:folinic acid as assessed by tissue distribution and pharmacokinetics of 5-FU, but was generally better tolerated as determined by weight loss, hematological and other clinical parameters. Compared to 5-FU:folinic acid, Fluorodex was also associated with reduced phlebitis using a rabbit ear vein model. Furthermore, equivalent to enhanced efficacy of Fluorodex compared to 5-FU:folinic acid against human carcinoma tumour models in mice was observed.

**Conclusions:** These novel all-in-one formulations represent a superior injectable form of 5-FU that allows co-delivery of folinic acid. This should translate to improved patient tolerability with potential for enhanced efficacy.

### Keywords

CMMB

### Disciplines

Life Sciences | Physical Sciences and Mathematics | Social and Behavioral Sciences

### Publication Details

This supplementary data is related to the following article: Stutchbury, T.K. et al., Preclinical Evaluation of Novel All-in-one Formulations of 5-Fluorouracil and Folinic Acid with Reduced Toxicity Profiles, *Anti-Cancer Drugs*, 2010 (in press).

### Authors

Tamantha K. Stutchbury, Kara L. Vine, Julie M. Locke, Jeremy S. Chrisp, J. B. Bremner, P Clingan, and Marie Ranson

## Supplementary Data

**Table S1** Haematology parameters – male rats

	<b>β-CD(HP) control</b>			<b>FD(HP)</b>			<b>5FU:FA</b>		
	Mean	SD	N	Mean	SD	N	Mean	SD	N
<b>WBC (x10<sup>9</sup>/L)</b>	8.43	1.39	4	2.40	1.10	4	2.33	2.70	4
<b><i>Neutrophils</i></b>	1.08	0.30	4	0.95	1.70	4	1.45	2.70	4
<b><i>Lymphocytes</i></b>	7.03	1.03	4	1.35	0.68	4	0.90	0.54	4
<b><i>Monocytes</i></b>	0.23	0.10	4	0.10	0.00	4	0.10	0.00	4
<b><i>Eosinophils</i></b>	0.1	0.00	4	0.1	0.00	4	0.1	0.00	4
<b>RBC (x10<sup>12</sup>/L)</b>	6.79	0.28	4	6.30	1.73	4	5.29	1.95	4
<b>Hgb (g/L)</b>	144.00	4.69	4	135.00	35.52	4	116.00	44.58	4
<b>Hct (L/L)</b>	0.43	0.02	4	0.39	0.10	4	0.33	0.13	4
<b>MCV (fL)</b>	62.95	1.41	4	61.80	1.50	4	61.30	2.51	4
<b>MCH (pg)</b>	21.20	0.32	4	21.45	0.31	4	21.88	0.39	4
<b>MCHC (g/L)</b>	336.75	4.11	4	347.50	3.51	4	357.25	8.96	4
<b>Plt (x10<sup>9</sup>/L)</b>	1120.50	133.68	4	315.00	527.44	3	111.25	216.50	4

WBC: while blood cell; RBC: red blood cell; Hgb: hemoglobin; Hct: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; Plt: platelets.

**Table S2** Haematology parameters – female rats

	<b>β-CD(HP) control</b>			<b>FD(HP)</b>			<b>5FU:FA</b>		
	Mean	SD	N	Mean	SD	N	Mean	SD	N
<b>WBC (x10<sup>9</sup>/L)</b>	5.95	0.70	4	2.30	0.69	4	1.10	0.35	4
<b><i>Neutrophils</i></b>	0.75	0.39	4	0.10	0.00	4	0.1	0.00	4
<b><i>Lymphocytes</i></b>	5.08	0.710	4	2.15	0.73	4	1.10	0.35	4
<b><i>Monocytes</i></b>	0.10	0.00	4	0.10	0.00	4	0.1	0.00	4
<b><i>Eosinophils</i></b>	0.10	0.00	4	0.1	0.00	4	0.1	0.00	4
<b>RBC (x10<sup>12</sup>/L)</b>	6.22	0.28	4	5.29	0.20	4	4.86	0.22	4
<b>Hgb (g/L)</b>	132.00	6.38	4	113.25	5.38	4	100.75	3.50	4
<b>Hct (L/L)</b>	0.39	0.01	4	0.31	0.01	4	0.29	0.01	4
<b>MCV (fL)</b>	62.60	1.89	4	57.93	0.92	4	59.60	0.66	4
<b>MCH (pg)</b>	21.23	0.83	4	21.48	0.33	4	20.78	0.76	4
<b>MCHC (g/L)</b>	339.00	6.22	4	370.50	4.43	4	348.25	9.18	4
<b>Plt (x10<sup>9</sup>/L)</b>	1049.50	92.31	4	44.50	16.84	4	3.25	4.50	4

WBC: while blood cell; RBC: red blood cell; Hgb: hemoglobin; Hct: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; Plt: platelets.